← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Aridis Pharmaceuticals, Llc
San Jose, CA
$12,716,779
Total funding
6
Grants
Funding over time
peak $5.8M · FY2005–16$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$12,716,779 · 6
By mechanism
N01$7,110,029 · 1
R42$2,922,383 · 1
R43$2,140,738 · 3
R41$543,629 · 1
Investigators at Aridis Pharmaceuticals, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Therapeutic Medical Countermeasures for Biodefense$4,784,675
N01 · FY2013 · AI
Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis$999,998
R42 · FY2012 · AI
Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis$999,998
R42 · FY2013 · AI
Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis$922,387
R42 · FY2011 · AI
Development of Therapeutic Medical Countermeasures for Biodefense$700,798
N01 · FY2015 · AI
Development of Therapeutic Medical Countermeasures for Biodefense$620,545
N01 · FY2015 · AI
Development of Therapeutic Medical Countermeasures for Biodefense$620,545
N01 · FY2015 · AI
Live, oral, heat Stable S. typhi TY21a vaccine$501,698
R43 · FY2006 · AI
Live, oral, heat Stable S. typhi TY21a vaccine$472,908
R43 · FY2005 · AI
Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis$299,997
R41 · FY2007 · AI
Inhalable Gallium Nitrate Anti-Infective Powder for CF$299,960
R43 · FY2009 · AI
Inhalable Gallium Nitrate Anti-Infective Powder for CF$299,869
R43 · FY2010 · AI
Stable Vaccines Delivered on Oral Thin Films$283,500
R43 · FY2014 · AI
Stable Vaccines Delivered on Oral Thin Films$282,803
R43 · FY2015 · AI
Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis$243,632
R41 · FY2008 · AI
Development of Therapeutic Medical Countermeasures for Biodefense$127,822
N01 · FY2016 · AI
Development of Therapeutic Medical Countermeasures for Biodefense$127,822
N01 · FY2016 · AI
Development of Therapeutic Medical Countermeasures for Biodefense$127,822
N01 · FY2016 · AI